Milestone! Gluetacs Therapeutics Commences First Patient Dosing in First-In-Human Phase I/IIa Trial to Assess GT929

ON：2024-03-06 TAG：GLUETACS THERAPEUTICS

PRESS RELEASE

Shanghai, China – 6 Mar. 2024

Gluetacs Therapeutics Commences First Patient Dosing in First-In-Human Phase I/IIa Trial to Assess GT929

Today, Gluetacs Therapeutics, has reached a significant milestone with the enrollment of the first patient in the Phase I/IIa clinical trial evaluating GT929, a molecular glue degrader from the GlueTacs^® platform. GT929’s initiation in this trial marks a pivotal step in addressing the urgent medical needs of patients with relapsed or refractory Non-Hodgkin lymphoma in China. The trial, focusing on dose escalation, aims to evaluate GT929’s safety, tolerability, pharmacokinetic profile, and efficacy.